(January 13, 2014) Researchers at Case Western Reserve University, led by OCRFA grantee Analisa DiFeo, PhD have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer – a finding that has the potential to improve outcomes for patients with the disease. The findings were published … Continued
Kicks off 20th Anniversary with an unprecedented grant award for scientific research and gynecologic cancer patient support program New York, NY January 13, 2014 — To mark its 20th anniversary, Ovarian Cancer Research Fund has awarded a record-breaking $6.9 million in scientific research grants for ovarian cancer and program grants to support gynecologic cancer patients. … Continued
OCRF has awarded $6.5 million in research grants to 22 scientists at leading medical institutions across the country.
A new combination therapy developed by researchers at the Roswell Park Cancer Institute has showed positive results in 60% of women with recurrent ovarian cancer. To develop the new therapy, researchers took advantage of the fact that ovarian cancer cells have abnormally high a marker called NY-ESO-1 on their surfaces. Researchers gave patients a drug … Continued
New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer. This suggests that this combinatorial “chemoimmunotherapy” may provide a new treatment option for patients with this disease. Results of this phase I clinical trial, which … Continued
(December 30, 2013) The U.S. Preventive Services Task Force (Task Force) has issued a final recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer in Women. This final recommendation statement applies to women who have no signs or symptoms of a BRCA-related cancer (cancer of the breast, ovary, fallopian tube, or … Continued
(December 20, 2013) Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival. The research was published online today in Gynecologic Oncology. Among patients with advanced-stage ovarian cancer, the provider combination of high volume hospital/high volume provider is an … Continued
Hope for Heather was established in memory of Heather Weeks, a young woman who lost her life to colon cancer but spent her 20s working on behalf of women with ovarian cancer. Heather’s family started the organization in March of 2009. Their original goal was to raise about $1,000 a year for ovarian cancer research; … Continued
A targeted drug delivery system developed at Rutgers University could possibly make ovarian cancer more treatable. The study results published in Clinical Cancer Research also indicated the new system could increase survival rates in ovarian cancer. Read the full article here.
Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro. The research, funded in part through an OCRF grant to senior author Ann Klopp, MD, PhD was published online last week in PLoS One. The researchers hypothesized … Continued
A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that shed light on the pathogenesis of ovarian cancer for BRCA1/2 mutation carriers. These models, which target the cell of origin (fallopian tube secretory cells) and recreate key genetic … Continued
OCRF Board Member, Robin Zarel, Celebrates 20 Years as an Ovarian Cancer Survivor.
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
